我要投票 桂龙咳喘宁在医疗器械行业中的票数:97
· 外 推 电 报 ·
2025-02-23 12:32:45 星期日

【桂龙咳喘宁是哪个国家的品牌?】

桂龙咳喘宁是什么牌子?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力桂龙咳喘宁品牌出海!通过在本页面挂载桂龙咳喘宁品牌的产品链接和联系邮箱,可以提高桂龙咳喘宁产品曝光!跨境电商爆单神器,目前只要100元/年哦~

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


英文翻译:Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://www.waitui.com/brand/0d765d197.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

上海市副市长陈杰:加快建设人工智能“上海高地”,壮大开源社区力量

36氪获悉,2月23日,2025全球开发者先锋大会在上海徐汇召开,上海市副市长陈杰出席开幕式并发表致辞。陈杰指出,面对人工智能快速迭代、模型开源的新趋势,上海将继续发挥超大城市的综合优势,加快建设更具国际影响力的人工智能“上海高地”。进一步完善开源开放生态系统,夯实“语料开放+模型开源”服务体系,不断壮大开源社区力量,推动基础模型、算法和数据资源的共享与开放,构建开放协作、互利共赢的创新环境。(中国基金报)

33分钟前

清华AIR联合水木分子开源DeepSeek版多模态生物医药大模型BioMedGPT-R1

36氪获悉,清华大学人工智能产业研究院(AIR)和北京水木分子生物科技有限公司近日携手推出了升级版的生物医药多模态开源基础大模型BioMedGPT-R1。此前,在2023年,双方合作发布了开源可商用、生物医药多模态百亿参数开源基础大模型BioMedGPT,水木分子发布了自研千亿参数多模态生物医药专业大模型Chat DD-FM和新一代AI驱动药物发现工具Chat DD。这次DeepSeek版ChatDD- R1基座模型也已同步上线ChatDD,赋能生物医药企业的药物研发。

33分钟前

TCL李东生:中国制造未来在海外最大增量大概率来自新兴市场

36氪获悉,TCL&奥林匹克全球合作伙伴签约仪式近日在北京举行。会后,TCL创始人、董事长李东生接受记者采访时表示,当前全球产业链面临转移与重构,持续由全球化向区域化、本土化方向发展。中国制造未来在海外最大的增量空间大概率来自新兴市场,比如巴西等新兴经济体。目前TCL海外制造基地分布在越南、马来西亚、菲律宾、印尼、印度、巴基斯坦、波兰、墨西哥、巴西等九个国家,实现东南亚、南亚、欧洲、北美、南美等各大区域本土化制造布局。未来,会持续关注新兴市场的增长潜力。

33分钟前

深圳:来深毕业生免费7天住升级为15天

为方便各地高校毕业生来深找工作,深圳相继推出“青年驿站”“深梦启航”“深梦扬帆”等“深梦”系列公益活动,为各地来深高校毕业生提供免费7天居住福利,解决他们阶段性、过渡性的居住需求。 2月23日,深圳市政府新闻办召开“打造最好科技创新生态和人才发展环境”新闻发布会。市委科创委办公室主任、科技创新局局长张林在会上透露,深圳为高校应届毕业生来深求职提供免费住宿天数,将从7天延长到15天。 (深圳特区报)

33分钟前

湖南规范互联网医院处方行为:严禁使用AI等自动生成处方

36氪获悉,湖南省医保局近日发布《关于进一步加强基本医疗保障定点零售药店管理的通知》。通知中提到,规范互联网医院处方行为。对互联网医院处方有如下几个措施:①压实实体医疗机构责任。依托实体医疗机构与市级医保部门签订补充协议,强化实体医疗机构的管理责任,因互联网医院违规被解除补充协议的原则上同步解除实体医疗机构医保定点协议,依托的实体医疗机构原则上应为二级及以上医疗机构。②纳入医保管理范畴。在本统筹区提供处方服务的由本市医保中心签协议后公布,跨市州提供处方服务的先征得药店所在地市级医保中心同意,再报省医保中心审定公布。③接入处方流转平台。互联网医院须按规定接入省医保电子处方中心并进行电子处方流转。④明确处方要求。处方行为必须符合行业主管部门管理办法,应与患者或患者家属进行有效、充分的沟通问诊,严禁使用人工智能等自动生成处方。

33分钟前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询